血浆内皮抑素可预测2型糖尿病患者的肾脏结局
研究基于ACCORD试验巢式病例对照(187例/187对照)和Mount Sinai BioMe队列(871例),评估血浆内皮抑素与复合肾脏结局(eGFR持续下降40%或终末期肾病)的关联。结果显示内皮抑素每log2升高,肾脏结局风险约增2.5倍(ACCORD OR 2.5, 95%CI 1.5-4.3;BioMe HR 2.6, 95%CI 1.8-3.8),最高vs最低四分位风险约4倍。在BioMe中,将内皮抑素加入基础临床模型使AUC从0.74提升至0.77。
要点
- 血浆内皮抑素与2型糖尿病患者肾脏复合结局独立强相关。
- 内皮抑素最高四分位者肾脏结局风险约为最低四分位的4倍。
- 加入内皮抑素可轻度改善传统预测模型的区分度(AUC 0.74→0.77)。
核心结论
- 血浆内皮抑素与2型糖尿病患者肾脏结局强烈相关,并可改善风险区分度。
研究设计与样本
- ACCORD试验巢式病例对照研究(187例病例,187例对照)。
- Mount Sinai BioMe Biobank当代2型糖尿病队列(n=871)。
主要发现
- 复合肾脏结局为eGFR持续下降40%或终末期肾病。
- 基线血浆内皮抑素水平在发生复合结局者中更高。
- 内皮抑素每log2增量:ACCORD调整OR 2.5(95%CI 1.5-4.3);BioMe调整HR 2.6(95%CI 1.8-3.8)。
- 最高vs最低四分位:ACCORD调整OR 3.6(95%CI 1.8-7.3);BioMe调整HR 4.4(95%CI 2.3-8.5)。
- BioMe中基础临床模型加入内皮抑素后AUC从0.74升至0.77。
临床怎么用
- 对于eGFR保留的2型糖尿病患者,可考虑检测血浆内皮抑素以辅助肾脏风险分层。
- 内皮抑素可作为传统预测指标之外的补充标志物,但尚未推荐常规临床应用。
局限性
- ACCORD为巢式病例对照设计,可能存在选择偏倚。
- 研究未报告内皮抑素检测标准化方法及成本效益。
- 外部验证队列有限,需更多人群验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel biomarkers are needed to predict kidney function decline in patients with type 2 diabetes, especially those with preserved glomerular filtration rate (GFR). There are limited data on the association of markers of endothelial dysfunction with longitudinal GFR decline. We used banked specimens from a nested case-control study in the Action to Control Cardiovascular Disease (ACCORD) trial (n=187 cases: 187 controls) and from a diverse contemporary cohort of type 2 diabetic patients from the Mount Sinai BioMe Biobank (n=871) to assess the association of plasma endostatin and kidney outcomes. We measured plasma endostatin at enrollment and examined its association with a composite kidney outcome of sustained 40% decline in estimated GFR or end-stage renal disease. Baseline plasma endostatin levels were higher in participants with the composite outcome. Each log2 increment in plasma endostatin was associated with approximately 2.5-fold higher risk of the kidney outcome (adjusted odds ratio [OR] 2.5; 95% confidence interval [CI] 1.5-4.3 in ACCORD and adjusted hazard ratio [HR] 2.6; 95% CI 1.8-3.8 in BioMe). Participants in the highest vs. lowest quartile of plasma endostatin had approximately four-fold higher risk for the kidney outcome (adjusted OR 3.6; 95% CI 1.8-7.3 in ACCORD and adjusted HR 4.4; 95% CI 2.3-8.5 in BioMe). The AUC for the kidney outcome improved from 0.74 to 0.77 in BioMe with the addition of endostatin to a base clinical model. Plasma endostatin was strongly associated with kidney outcomes in type 2 diabetics with preserved eGFR and improved risk discrimination over traditional predictors.
引用
- Chauhan K, Verghese DA, Rao V, et al. Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes. Kidney Int. 2018. PMID: 30591223. doi:10.1016/j.kint.2018.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。